Note: The following is an excerpt from a press release from Alnylam Pharmaceuticals, Inc. regarding news from their recent presentation at the American Society of Hematology (ASH) Annual Meeting. The original article can be read in its entirety here.


Alnylam Pharmaceuticals, Inc. presented data from the phase 1 study of fitusiran at the ASH meeting. The pharmaceutical company shared that investigational drug has helped to control bleeding in a subset of hemophilia patients who have previously been hard to treat.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.